Chimicles & Tikellis is investigating a potential class action lawsuit on behalf of Medicare patients that have received a BRAC 1 genetic test from Myriad Genetics. There have been reports that Myriad is categorizing the test as “screening” instead of “diagnostic”, resulting in Medicare denying coverage and patients paying for the test out of pocket. Patients with the BRAC 1 gene have a predisposition to developing breast cancer. The BRAC 1 genetic test is an influential test in determining a patient’s treatment. Myriad Genetics is the sole processor of BRAC 1 genetic tests. C&T is investigating reports that Myriad Genetics has improperly denied Medicare coverage, requiring patients to pay out of pocket and is seeking to recover on behalf of those patients.

If you have received a BRAC 1 genetic test from Myriad Genetics and paid out of pocket please contact the attorneys below: